Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Growing evidence suggests that urinary and sexual functional outcomes after radical prostatectomy for prostate cancer differ based on race, with Black men experiencing worse outcomes. Alongside efforts to improve quality and equity, incorporating patient-reported outcomes measures into patient care could improve equity in treatment outcomes for men with prostate cancer.
The treatment landscape for localized prostate cancer is rapidly evolving to achieve oncological disease control, simultaneously preserving gastrointestinal and genitourinary function. Focal therapy using cryoablation is an emerging treatment for prostate cancer. Short-term and intermediate-term clinical data on focal cryoablation therapy in prostate cancer have shown promising oncological and functional outcomes.
The approval of immunotherapy agents to treat patients with metastatic renal cell carcinoma revolutionized the therapeutic landscape for this disease, but a large number of patients still do not experience objective and durable response, and biomarkers to identify response to immunotherapy are urgently needed. In this Review, the authors describe strength and limitations of currently available prognostic and predictive biomarkers in metastatic renal cell carcinoma and discuss emerging promising biomarkers that deserve further investigation.
In this Review, the authors provide a comprehensive overview of various in vitro, ex vivo and in vivo models of prostate cancer and discuss their respective advantages and limitations in the context of current needs and challenges in prostate cancer research and therapy.
Adjuvant therapies in renal cell carcinoma (RCC) disrupt multiple steps of the metastatic cascade. Results from clinical trials to assess adjuvant treatment with immunotherapeutic agents in patients with resected clear cell RCC were promising, but the utility of tyrosine kinase inhibitors in this setting was not clearly shown. In this Perspective, the authors provide an overview of completed and ongoing clinical trials for adjuvant treatment of RCC, highlighting future directions and challenges in the field.
